Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab

X
Trial Profile

Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated with Ustekinumab

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary) ; Ustekinumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms STARDUST; STARDUST LTE
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 30 Nov 2023 Results (n=323) from long-term extension period assessing clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease through week 104 published in the Alimentary Pharmacology and Therapeutics
    • 11 Oct 2022 Results (n=323) assessing the long-term extension period for health-related quality of life measures and the effect of ustekinumab on work productivity and activity impairment at week 104, comparing treat-to-target and standard of care, presented at the 30th United European Gastroenterology Week.
    • 11 Oct 2022 Results of incorporated-intestinal ultrasound sub-study (n=77) assessing incorporated-intestinal ultrasound endpoints and their relation-ship with ustekinumab exposure presented at the 30th United European Gastroenterology Week.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top